Tapencarium (RZL-012) for Flank Fat Reduction: A Proof-of-Concept Study.

ABSTRACT:

Background

RZL-012 is a novel cytolytic drug that has shown promise in reducing localized fat deposits in a single treatment session.

Objectives

To assess the safety and efficacy of injecting RZL-012 to the flanks.

Methods

A double-blind, placebo-controlled, proof of concept study randomized 12 patients to receive RZL-012 injections in 1 flank and placebo injections in the contralateral flank. After 12 weeks of follow-up, patients could receive RZL-012 in the placebo-treated flank and undergo follow-up for 12 weeks in the open-label phase.

Results

At 12 weeks, Investigator Global Aesthetic Improvement Scale assessments showed improvement for 90.9% of RZL-012-treated flanks and 0% of placebo-treated flanks (P < .0001), 81.8% of patients were satisfied wit

SUBMITTER: Shridharani SM 

PROVIDER: S-EPMC10631968 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature